AstraZeneca Presents (XALOC) Programme Results of Fasenra (benralizumab) for the Treatment of Severe Eosinophilic Asthma at ERS 2022
Shots:
- The (XALOC) RWE program consists of (XALOC-1 & 2) study evaluating Fasenra in 750+ & 400+ patients along with the (ImPROve Asthma) study in Germany with SEA
- The (XALOC-1) study results showed an AAER reduction of 84% @48wk. over baseline in an overall patient population, reduction in AAER of 79–91% across patient subgroups regardless of atopic status, CRSwNP comorbidity, maintenance OCS use, FeNO & blood eosinophil cut-offs, improvements in asthma control
- The (ImPROve Asthma) study, part of the (XALOC-2) study showed improvements across PROs measures in the total SEA cohort & CRSwNP, 35% achieved clinical remission @6mos. in a real-world setting & 44% with SEA & comorbid CRSwNP, and no decrease of forced expiratory volume in FEV1 ≥200 mL vs baseline
Ref: Pharmiweb | Image: AstraZeneca
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
